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Abstract
The purpose of present review is to describe the effect of leucine supplementation on skeletal
muscle proteolysis suppression in both in vivo and in vitro studies. Most studies, using in vitro
methodology, incubated skeletal muscles with leucine with different doses and the results suggests
that there is a dose-dependent effect. The same responses can be observed in in vivo studies.
Importantly, the leucine effects on skeletal muscle protein synthesis are not always connected to
the inhibition of skeletal muscle proteolysis. As a matter of fact, high doses of leucine incubation
can promote suppression of muscle proteolysis without additional effects on protein synthesis, and
low leucine doses improve skeletal muscle protein ynthesis but have no effect on skeletal muscle
proteolysis. These research findings may have an important clinical relevancy, because muscle loss
in atrophic states would be reversed by specific leucine supplementation doses. Additionally, it has
been clearly demonstrated that leucine administration suppresses skeletal muscle proteolysis in
various catabolic states. Thus, if protein metabolism changes during different atrophic conditions,
it is not surprising that the leucine dose-effect relationship must also change, according to atrophy
or pathological state and catabolism magnitude. In conclusion, leucine has a potential role on
attenuate skeletal muscle proteolysis. Future studies will help to sharpen the leucine efficacy on
skeletal muscle protein degradation during several atrophic states.
Introduction
Skeletal muscle atrophy is considered an important public
health problem due to its primary (metabolic alterations)
and secondary consequences (strength loss, decreased
autonomy). As known, the atrophy process becomes
apparent when skeletal muscle protein degradation is
increased above protein synthesis during a prolonged
period of time. In this context, leucine supplementation
seems to be a promising anti-atrophy therapy, acting
either by inhibiting skeletal muscle proteolysis and/or
increasing protein synthesis, an effect which may possibly
be both dose-dependent as well as skeletal muscle atrophy
condition-dependent. This review will discuss the effects
of leucine supplementation in the regulation of skeletal
muscle proteolysis in both, in vitro and in vivo studies.
Anti-atrophy effects of Leucine Supplementation
The sparing protein effects of leucine supplementation
have been known since the initial studies of Buse & Reid
(1975) [1]. Due to its properties of isolated action, leucine
is actually considered not only an AA constituting protein,
but also a physiopharmacological entity, whose adminis-
tration is capable of promoting important anti-catabolic
actions, such as attenuation of skeletal muscle catabolism
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during weight loss, facilitation of a healing process and
improvement of skeletal muscle protein turnover in aged
individuals [2,3].
In general, leucine supplementation consistently demon-
strates decreases in skeletal muscle proteolysis when
infused intravenously [4-8], incubated with the whole
muscle [1,9-11], incubated with skeletal muscle cells
[12,13] and under oral feeding [14]. It should be noted
that the magnitude of inhibition is different according to
the species, pathological condition and, especially, to the
atrophy model. Importantly, in skeletal muscle cell cul-
tures the antiproteolytic effects of leucine supplementa-
tion also occurs, but in this system the leucine dose-
dependent effect appears to be shifted to a low concentra-
tion range when compared to the whole muscle incuba-
tion [15].
In chronic studies leucine supplementation efficacy is not
as well demonstrated as in acute ones, but in this level leu-
cine supplementation also shows important antiproteo-
lytic effects. As a matter of fact, a recent study performed
by Combaret et al. (2005) [14] showed that oral chronic
leucine supplementation (~0.7 g/kg/day over a period of
10 days) presented long-lasting inhibitory effects on skel-
etal muscle proteolysis by around ~30%, restoring the
defective postprandial inhibition of proteasome-depend-
ent proteolysis. Also supporting the evidence of decreased
proteolysis induced by leucine supplementation, a study
performed by Ventrucci et al. (2004) [16] showed that in
cancer cachexia-tumor induced rats, the consumption of
an leucine enriched diet (3%) over a period of 20 days
reduced protein degradation in gastrocnemius muscles by
around 11%, increasing the myosin heavy chain content
by around 47%. Recently, with the same study design,
Eley et al. (2007) [17] demonstrated that the consump-
tion of 1 g/kg/day of BCAA for 12–15 days suppresses the
body weight loss by around 33% and decreases protein
degradation by around 62% in soleus muscles. However,
on the contrary, Sadiq et al. (2008) [18] showed that in
calves, 5 days of intravenous infusion of EAA (rendering
leucine plasmatic levels ~0.24 mM) under energy and pro-
tein deficits improved nitrogen balance, but the skeletal
muscle proteolysis was not attenuated. Overall, chronic
studies shown leucine supplementation as an important
anti-atrophy strategy, but the lack of standardization
related to the leucine supplementation dose (ingested and
absorbed) impairs major conclusions related to the mag-
nitude of effect. Table 1 summarizes important studies
related to the leucine effects on skeletal muscle proteolysis
in both humans and animals.
Acute Leucine Supplementation: Relationship between 
Dose and Effect
To bring about the efficacy of AA supplementation, it is
necessary to understand its dose-effect properties. In this
respect, Michael Rennie's group has made important dis-
coveries related to the existence of a curvilinear dose-
response relationship between the extra cellular EAA (par-
ticularly leucine among these) and the human skeletal
muscle protein synthesis [19]. The concept is that under
normal conditions, a single meal appears to promote
maximum effects on protein synthesis. This finding is
based on studies performed in both adult rats and adult
humans, showing that the leucine plasma concentration
in the PA state is approximately 0.1 mM [20,21] and in the
PP state, it is increased approximately 80% or more, ren-
dering mean values of 0.2 mM. This value seems to be
capable of promoting maximum increases in the protein
synthesis and of saturating the system [19,20].
When the issue is inhibition of protein degradation, much
less is known about this property of dose-effect, even in
animal studies. The results presented in the literature
show variations, based on the skeletal muscle studied, the
isotope utilized to measure protein metabolism and the
system studied (in vitro vs in vivo studies). However, a
deeper analysis of these studies, especially in vitro studies
(where it is possible to simultaneously detect the protein
synthesis and protein degradation metabolism), reveals
new findings despite methodological differences. Thus, a
re-interpretation of these studies is warranted to generate
a new concept about a leucine dose-effect relationship.
In skeletal muscle cell cultures, the absence of aminoacids
(especially leucine), appears to control protein degrada-
tion mainly through the activation of lysosome-depend-
ent proteolysis [15,22] Additionally, during whole muscle
incubations, leucine supplementation leads to a
decreased ATP-ubiquitin-dependent proteolytic activity
[11]. However, there is still no current mechanistic infor-
mation about how the nutritional signal induced by AA is
sensed by the muscle cell (i.e. intracellularly or extracellu-
larly). Several studies by Mortimore and colleagues
[23,24] and Pösö et al. (1982) [25], showed that in the
liver, the extra cellular concentration of AA dictates in a
dose-dependent fashion, the inhibition of proteolysis
inside the liver cells, and that among AA, leucine was the
strongest inhibitor.
When related to skeletal muscle, the intracellular AA con-
centration is not available in most studies. However,
based on the extra cellular AA concentrations (plasmatic
levels and/or extra cellular levels) it is possible to assume
that the leucine concentration present to control the pro-
tein synthesis is also available to control the protein deg-
radation, regardless of the mechanism process. Based onNutrition & Metabolism 2008, 5:20 http://www.nutritionandmetabolism.com/content/5/1/20
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Table 1: Effects of leucine supplementation on animal e human studies related to skeletal muscle protein turnover
Study Duration Dose Methods Results
Human
4 180 min L-leucine: 1.09 and or 1.74 μmol/kg/
min with insulin (plasma: 208 and 207 
μmol/L) (infusion)
Leucine + KIC rates of appearance; 
KIC oxidation; Leucine-carbon flux
Leucine 1.09 μmol/kg/min stimulated leucine 
deposition into body protein in 37.7% but did 
not suppress endogenous proteolysis; Leucine 
1.74 μmol/kg/min with insulin had a cumulative 
effect of 49.9% on net leucine deposition into 
body protein.
5 7 h L-leucine: 154 ± 1 mmol/kg-1/h-1 
(infusion)
Whole-body valine and 
phenylalanine (tracers) flux
Inhibition of protein degradation without 
causing an increase in protein synthesis.
6 16 h BCAA: 1.66 μmol/kg/min (infusion) Whole-body (arterial and venous) 
leucine and phenylalanine (tracers) 
flux rates
Suppressed rate of whole-body (-37%) and 
forearm (-43%) muscle proteolysis.
Rat
8† 105 min BCAA: 246 mg/kg-1/h-1 (infusion) - Neither muscle protein synthesis nor 
breakdown affected.
9 NR L-leucine: 0.1, 0.2, 0.25 and/or 0.5 mM 
(muscle incubation)
Rate of 14CO2 and KIC production Protein synthesis was stimulated in: 10% (0.1 
mM), 19% (0.2 mM) and 42% (0.5 mM); 
Protein degradation was inhibited in: 0% (0.1 
mM), 6% (0.2 mM), 15% (0.25 mM) and 26% 
(0.5 mM).
1 2 h L-leucine: 0.5 mM (muscle incubation) Incorporation of tyrosine (tracer) 
into proteins
Leucine increased the specific activity of the 
proteins by 25% and incorporated tissue 
proteins by 11.5%.
27 2 h L-leucine: 0.5 mM (muscle incubation) Rate of tyrosine (tracer) 
incorporated and released
Protein synthesis was stimulated in the soleus 
muscles by 69% and in EDL muscles by 38%. 
No effects on protein degradation were 
observed.
12 NR L-leucine: 5 mM (muscle incubation) Release of acid-soluble 3H-tyrosine 
(tracer)
Leucine caused a significantly reduction in 
proteolysis of -8 to 12%.
11 NR L-leucine: 10 mM (muscle incubation) Rate of tyrosine (tracer) released Decreased whole-body proteolytic rate in 
25%.
14 10 d L-leucine: ~0,7 g/kg/day* (ingestion) Rate of tyrosine (tracer) released Suppressed postprandial proteolysis in old 
rats in 40% (measured by proteasome-
dependent proteolysis).
17 12–15 d BCAA: 1 g/kg/day* (ingestion) Incorporation of L- [2,6-
3H]phenylalanine and release of 
tyrosine (tracers)
Suppression on the loss of body weight (-1.5 
vs. -4.5 g of control group); increase in rate of 
protein synthesis in gastrocnemius muscle 
(~50–60%) and in weight of the soleus muscle 
(~0.007 g); decrease of protein degradation in 
soleus muscle (-1500 g/2 h measured by 
fluorescence).
Mice
16 20 d L-leucine: ~4.2 g/day* (ingestion) Rate of incorporation of [3H]-
phenylalanine and release of 
tyrosine (tracers)
Protein synthesis was higher around 23.4% 
and degradation reduced in by around 11% 
with leucine supplementation.
Calves
18 5 d L-leucine: 239.6 μmol/L (infusion) Urea creatinine, urea nitrogen and 
urea 3-methyl-histidine levels
Improvement on nitrogen balance without 
effect on protein degradation
† = Unpublished results; *Relativized according to the data provided; AA = amino acid; BCAA = branched-chain amino acids; KIC = [1-14C]alpha-
ketoisocaproate acod; NR = Not related.Nutrition & Metabolism 2008, 5:20 http://www.nutritionandmetabolism.com/content/5/1/20
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this assumption, the results of several studies are summa-
rized below. They suggest that the leucine dose capable of
causing maximal effects on protein degradation may be
higher than that capable of causing maximal effects on
protein synthesis during negative protein-balance condi-
tions. However, this dose-dependent effect seems not
occur in skeletal muscle cell cultures [15].
Animal Studies
In an earlier study in 1977, Buse & Weigand [26] showed
that rat diaphragm muscles incubated with a leucine con-
centration of 0.5 mM (twice that of leucine concentration
found in the PP state) was capable of increasing the skele-
tal muscle protein synthesis in 36–38%. Nevertheless, the
protein degradation was inhibited in 4.7%, indicating
that a high physiological leucine concentration is capable
of both, strongly stimulating the protein synthesis and to
a lesser extent, of inhibiting the protein degradation, even
in the absence of a hormonal supply. In agreement with
this, Tischler et al. (1982) [9], incubated rat diaphragm
muscles with a wide leucine concentration (ranging from
PA to PP state). They observed that a leucine concentra-
tion of 0.1 mM significantly increased the skeletal muscle
protein synthesis. However, this same leucine concentra-
tion (0.1 mM) did not affect the rates of protein degrada-
tion, which were altered only when the leucine
concentration was increased to a range from 0.2 to 0.5
mM. Within this range of concentration, protein degrada-
tion progressively diminished by a greater absolute
amount than that which stimulated protein synthesis
(Table 1).
In order to verify whether these results were observed only
when AA were administered in vitro, Kee et al. (2003) [7]
made a study using the extensor digitorum longus mus-
cles, with the nutritional supply being provided during in
vivo conditions (infused), in the presence of endogenous
hormonal factors. The results showed that in 48 h starved
rats, 4 h of AA infusion elevated the leucine plasma levels
to values of approximately 0.57 mM. This increase on leu-
cine plasma levels was capable of restoring the insulin and
corticosterone levels to values observed in the controlled
rats, concomitantly increasing the skeletal muscle protein
synthesis in 55.6%. However, at the same leucine concen-
tration, the skeletal muscle proteolysis was diminished to
only 17.9% (value nonstatistically different from the
starved group), suggesting that even in the presence of
hormonal factors, the leucine concentration capable of
stimulating the protein synthesis is attenuated when com-
pared to protein degradation.
In another study, Hong & Layman (1984) [27] analyzed
soleus muscles of starved rats (24 h and 72 h of fasting)
incubated with leucine (0.5 mM). They observed that in
the 24 h and 72 h fasted rats, protein synthesis was
increased 59% and 24% respectively, but the protein deg-
radation was not altered utilizing this leucine concentra-
tion in the soleus muscles. On the contrary, Busquets et al.
(2000) [11], incubated rat soleus muscles with a higher
leucine concentration of 5 mM and 10 mM. They
observed that the skeletal muscle proteolysis was inhib-
ited in a dose-response manner, i.e., leucine concentra-
tions of 5 mM caused an inhibition of 5.7% in proteolysis,
whereas 10 mM had caused an inhibition of 24.5%. This
study reveals that increasing the leucine concentration to
values 10–20× that of those observed in the other studies,
was capable of bringing about decreases in skeletal muscle
proteolysis, a result that is in accordance with another
study conducted by Mitchell et al. (2004) [12] that
observed that incubating skeletal muscle cells with a leu-
cine concentration of 5 mM was capable of inhibiting
skeletal muscle proteolysis in 8–12%. Thus, a plateau for
a leucine concentration related to inhibition of skeletal
muscle protein degradation during in vitro conditions was
not yet established, but these studies suggest that a leucine
concentration 10–20× superior to the one had in the PP
state (~0.2 mM) is still capable of exerting its anti-proteo-
lytic effects.
A limitation of the above studies was that although in
vitro measurements qualitatively  reflect rates of protein
turnover that were present in the intact animal before the
incubation period, the protein metabolism measured in
the whole muscle during in vitro conditions was always in
a pronounced state of negative protein balance even in
control muscles [7]. However, this situation could mimic
the one observed in an in vivo atrophic condition, where
skeletal muscle protein degradation is increased over pro-
tein synthesis [28]. Thus, under certain atrophic condi-
tions, it is possible that the amount of supplemented
leucine capable of maximally inhibiting muscle proteoly-
sis might be larger than that used to produce maximal
effects on protein synthesis.
Human Studies
At the present, accurate methodologies have been utilized
to measure protein synthesis in vivo but when the issue is
protein degradation, different methods have presented
important limitations, especially when related to protein
degradation in muscle. For example, the urinary excretion
of 3-methyl-histidine (3-MH) has been extensively used
to estimate muscle protein breakdown, both in experi-
mental animals and humans [29]. The rationale for using
urinary 3-MH as a measure of skeletal muscle proteolysis
is that the major portion of 3-MH is present in muscle
actin and myosin and importantly, 3-MH is not reutilized
for protein synthesis, being an index of protein degrada-
tion [30]. However, the specificity of urinary 3-MH excre-
tion has been challenged, especially under in vivo
conditions, because under some atrophic conditions likeNutrition & Metabolism 2008, 5:20 http://www.nutritionandmetabolism.com/content/5/1/20
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surgical trauma it was observed a disproportional over-
production of 3-MH from nonmuscle sources [31].
Another methodology adopted in vivo to measure protein
degradation is to follow the loss of radioactivity from pro-
tein previously labeled by the administration of radioiso-
tope tracer. When this method is used, a major concern is
that radioactive AA derived from protein breakdown,
enters the precursor pool and is reutilized for protein syn-
thesis. Such recycling of labeled AA results in apparent
breakdown rates which underestimate the true degrada-
tion rates [32]. Finally, an important question is the con-
tribution of whole body versus skeletal muscle tissue in
the protein degradation rates. To solve this question, sev-
eral human studies [33,34] have utilized the arteriov-
enous net balance (NB) technique to evaluate rates of
protein synthesis and protein breakdown in limbs (which
are mostly muscle), and the amino acid phenylalanine
has been used to trace muscle protein because it is neither
produced nor metabolized in muscle. Using this tech-
nique, muscle protein breakdown can be estimated from
the calculated value for the rate of phenylalanine appear-
ance to the vein, during a steady state in the concentration
of blood amino acids. However, a general problem with
the use of either the forearm or leg arteriovenous NB tech-
nique to evaluate muscle metabolism acutely, is that this
approach has practical limitations associated with the
time and the blood required and, more importantly, does
not permit the evaluation of short-lived effects on muscle
protein metabolism [35], difficulting dose-response stud-
ies of proteolysis. At all, while there is a lack of reliable
methods for measuring in vivo protein degradation in
skeletal muscle, whole body protein breakdown can be
estimated from the flux of radiolabeled or stable isotopes
in plasma or nitrogen in urine.
Several authors have demonstrated that leucine as well as
or BCAA supplementation (oral or infused) is capable of
both, increasing protein synthesis [4,36,37] or decreasing
protein degradation in humans [5,38,39]. There is a gen-
eral tendency in most human studies to demonstrate that
leucine supplementation is capable of promoting protein
sparing effects, mostly due to inhibition of protein degra-
dation [40]. Although the decline of proteolysis seemed to
occur in several studies, there is no consensus of a dose-
response relationship. For example, Tessari et al. (1987)
[4] infused an AA solution in subjects (PA state) for 180
min, reaching leucine plasmatic levels of 0.2 mM, and no
effects on endogenous proteolysis suppression were
found, whereas Castellino et al. (1987) [41] infused an AA
solution (subjects in the PA state) that rendered a leucine
plasmatic concentration of 0.28 mM over a period of 180
min, and showed that the endogenous leucine flux (an
indicator of proteolysis) was reduced 41.8% when com-
pared to the basal period. These differences may be related
to different methodologies used to analyze protein degra-
dation, as suggested by Matthews (2005) [40] or even
related to differential forms of leucine/AA administration
in these studies, a limitation also observed in studies
investigating skeletal muscle protein synthesis.
As stated above, there is no consensus about a dose-
response relationship in human studies related to leucine
supplementation and skeletal muscle proteolysis. How-
ever, a study performed by Sherwin (1978) [37] showed
that obese subjects submitted to 3 days of fasting pre-
sented basal leucine levels almost doubled (0.22 mM)
when compared to controlled subjects in the PA period, a
leucine concentration normally capable of maximally
stimulating the skeletal muscle protein synthesis in the PP
period, under normal conditions. In this study, leucine
infusion elevated leucine plasmatic concentration in 68%
above the controlled subjects after two hours of infusion
and 124% above the controlled subjects after 12 h (0.81
mM), under the same infusion rate. This acute leucine
infusion (day 4 of fasting) was still capable of improving
the nitrogen balance, returning to the previous levels on
the day after the infusion. These results suggest that the set
point  of protein turnover metabolism related to the
infused leucine concentration was up regulated in these
subjects. In this study, the protein degradation was not
inhibited by leucine infusion (measured by 3-methyl-his-
tidine release), but the nitrogen balance was improved
23% after 12 h of leucine infusion. A recent study per-
formed by Bohé et al. (2001) [42], indicated that in
humans, infusing a solution composed of mixed AA in a
rate that rendered a leucine plasmatic concentration of 0.4
mM, was capable of stimulating the protein synthesis for
only two hours, returning to basal states after this period
of time. Thus, it is possible that the inhibition of skeletal
muscle degradation might also be contributed to the
nitrogen sparing response during the 12 h of leucine infu-
sion, at least in nonmuscular tissues.
Very recently, an interesting study made by Katsanos et al.
(2006) [43], compared, in young and elderly subjects, the
consumption of an oral solution composed of EAA con-
taining a leucine concentration of 26% (which contained
similar leucine values encountered in the whey protein)
against the consumption of an EAA solution enriched
with leucine 41%, on skeletal muscle protein metabolism.
They observed that in young subjects, low dose leucine
supplementation (26%) was capable to increase the skel-
etal muscle protein synthesis, whereas in the elderly sub-
jects no effect was observed (although in both groups,
similar plasmatic leucine levels were achieved ~0.45 mM).
However, when a mixture containing high leucine con-
centration (41%) was supplemented, the elderly group
increased the skeletal muscle protein synthesis to compa-
rable values observed in young subjects, restoring the
defective nutritional response observed in a low leucineNutrition & Metabolism 2008, 5:20 http://www.nutritionandmetabolism.com/content/5/1/20
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supplemented dose (although again, in both groups, sim-
ilar plasmatic leucine levels were achieved ~0.65 mM).
Importantly, only the elderly subjects supplemented with
the 41% enriched leucine solution presented a strong ten-
dency to inhibit protein degradation. It is possible that in
the elderly, a higher leucine supplementation dose will be
capable to inhibit even more the muscle protein degrada-
tion, but this hypothesis was not yet tested.
Summing up, in human studies, leucine supplementation
clearly induces an inhibition in skeletal muscle proteoly-
sis and there are some sparse results suggesting that the
leucine concentration capable of diminishing protein
degradation may be larger than that capable of maximally
stimulating the protein synthesis, especially under
atrophic conditions.
Summary and Conclusion
In the last few years, several studies have provided impor-
tant advances on the understanding of how the feeding
process is involved in the maintenance of skeletal muscle
mass. After meal consumption, the feeding process pro-
vides in a coordinated fashion, rapid increases (~1–2
hour) in the skeletal muscle protein synthesis and inhibi-
tion of skeletal muscle protein degradation [44] that must
be gradually reversed in the fasting period between each
meal. The master nutritional signal involved in such
responses appears to be the BCAA leucine [45]. However,
after a prolonged atrophy state as that mediated by 48 h
starvation in young rats, 4 h of AA infusion almost com-
pletely restores the protein synthesis process, whereas
skeletal muscle proteolysis is not significantly affected [7].
Thus, under certain atrophic conditions, the nutritional
signal provided by leucine does not appear to be simply
the opposite way of the protein synthesis and protein deg-
radation process. It is important to note that increasing
the leucine concentration to values 10–20× superior (5–
10 mM/L) to that capable of promoting maximal
increases on protein synthesis, is still capable of exerting
its skeletal muscle anti-proteolytic effects in a dose-
dependent fashion [11]. Such evidences suggest that the
nutritional dose-effect relationship provided by the leu-
cine signal during certain atrophic conditions would be
considered separately when related to skeletal muscle pro-
tein synthesis and skeletal muscle protein degradation. In
agreement with this concept, during atrophic states as fast-
ing and denervation, there are evidences that the protein
degradation mechanisms are increased to an equal or
even to a greater extension than that caused by the dimin-
ished protein synthetic mechanisms [46,47], but after a
prolonged skeletal muscle inactivity period (28 days of
bed rest with concomitant cortisone treatment), the atro-
phy process seems to be strictly related to the inhibition of
protein synthesis [48]. Thus, if protein metabolism
changes during different atrophic conditions, it is not sur-
prising that the leucine dose-effect relationship must also
change, as stated by Kobayashi and colleagues [8]. An
important final consideration is related to the safety of
leucine supplementation. BCAAs supplementation has
minimal calories, does not stimulate gluconeogenesis,
and does not increase the glomerular filtration rate that is
reported to occur with alanine [2]. However, leucine is
considered an important insulin secretagogue, and high/
prolonged leucine supplementation is suggested to impair
the glucose metabolism. As an example, an important
study performed by Anello et al. (2001) [49], showed that
chronic exposure of rat pancreatic islets to high (20 mM)
leucine levels exhibited selectively impaired glucose-
induced insulin release, but high leucine levels reported in
the above study (1–10 mM) does not impaired the insulin
secretion (although glucose skeletal muscle metabolism
was not evaluated in this study). Future studies will help
to sharpen the leucine efficacy and safety on skeletal mus-
cle protein degradation during several atrophic states.
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